18:31 , Nov 15, 2017 |  BC Extra  |  Politics & Policy

Options provision culled, carried interest untouched in latest Senate bill

The Senate Finance Committee released a modified version of tax reform legislation late Tuesday night that scraps the provision that would have taxed stock options at vesting and again leaves the tax treatment of carried...
02:13 , Mar 10, 2017 |  BioCentury  |  Politics, Policy & Law

Stand up for science

The biopharma industry has done itself no favors by staying on the sidelines for two months as FDA’s fate has been debated in the White House and Trump Tower. To the contrary, this duck and...
07:00 , Aug 1, 2016 |  BioCentury  |  Strategy

Bug battle plan

Tired of waiting for the international community to organize proactive responses to the threats posed by emerging infectious diseases, GlaxoSmithKline plc has developed plans and is soliciting government support to create a permanent, independent entity...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

JNJ-42165279: Phase II hold

Johnson & Johnson’s Janssen Research & Development unit voluntarily suspended dosing in a double-blind, placebo-controlled, international Phase II trial evaluating 25 mg oral JNJ-42165279 in about 140 patients. The move follows the death of a...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

JNJ-42165279: Phase II hold

Johnson & Johnson’s Janssen Research & Development unit voluntarily suspended dosing in a double-blind, placebo-controlled, international Phase II trial evaluating 25 mg oral JNJ-42165279 once daily for 12 weeks in about 122 patients. The move...
07:00 , Oct 22, 2015 |  BC Innovations  |  Translation in Brief

TB memory

A New Orleans team has created a live attenuated tuberculosis vaccine that induces greater protection in monkeys than the standard BCG. While there's one more virulence gene to knock out, the group believes the compound...
08:00 , Dec 15, 2008 |  BioCentury  |  Regulation

Diabetes safety test

FDA...
08:00 , Dec 17, 2007 |  BioCentury  |  Regulation

Cardio panel not converted

FDA advisory committee meetings often focus on narrow technical or statistical issues specific to the compound up for review that can tip the balance between approval or rejection. The agenda for last week's meeting of...
07:00 , Sep 10, 2007 |  BioCentury  |  Regulation

NICE's Velcade gotcha

Although the U.K.'s NICE has relented to provision of Velcade bortezomib for multiple myeloma patients under its pay-for-performance agreement with Janssen-Cilag Ltd., it has found another way to limit reimbursement for the drug that patient...
07:00 , May 23, 2005 |  BioCentury  |  Finance

Ebb & Flow

This year's American Society of Clinical Oncology conference saw muted moves compared with the run up in the months preceding last year's conference and the hosing that cancer companies received during and after last year's...